EGFR mutation in lung cancer: tumor heterogeneity and the impact of chemotherapy.

Abstract excerpt

EGFR inhibitors have been examined as treatments for unselected NSCLC patients until the discovery that activating EGFR mutations render the tumors highly sensitive to these drugs (1,2). Since then, several studies have demonstrated that the presence of an EGFR activating mutation identifies a different population of NSCLC patients, with a significantly better prognosis, provided EGFR inhibitors are one of the...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Cancer Genomics and Diagnostics
• Share to Lung Cancer Research Studies
• Share to Lung Cancer Treatments and Mutations